Bioproduction Segment Held Largest Share of Cell Line Development Serum Market in 2019
According to our latest study on “Cell Line Development Serum Market Forecast to 2027 – COVID-19 Impact and Global Analysis – by Type and Application,” the market is expected to reach US$ 1,467.92 million by 2027 from US$ 915.58 million in 2019; it is estimated to grow at a CAGR of 6.1% from 2020 to 2027. The report provides trends prevailing in the global cell line development serum market, and the drivers and hindrances pertaining to the market growth.
Regenerative medicines have the potential to replace or heal tissues, as well as organs, and normalize congenital defects. Certain age-related abnormalities, diseases, and trauma damage the tissues and organs. Over the last decade of a century, the tissue engineering industry has emerged impressively, and it has now evolved into the broader area of regenerative medicine, which focuses on the development of clinical therapies for the maintenance, repair, replacement, and enhancement of biological function, with the use of cell engineering. Cell line development is a crucial and invariable part of regenerative medicine. Thus, advancements in the regenerative medicine boost the demand for serum used in cell line development.
The stem cells play a crucial role in regenerative medicine research revolves around the use of various types of stem cells such as adult, embryonic, induced pluripotent cells. Cell lines play a major role in testing and development of drugs, development of cell-based therapy, and research related to cancer tissues, among other applications. New drugs developed in pharmaceutical companies are safely and effectively tested on differentiated stem cells for checking their potential. Further, the regenerative medicines using cell-based models have the potential to help the researchers in early-intervention treatment for degenerative diseases and traumatic injuries. Thus, surge in the use of regenerative medicines propels the cell line development serum market.
Based on type, the global cell line development serum market is segmented into fetal bovine serum, adult bovine serum, porcine serum, horse serum, other animal serum. In terms of application, the market is segmented into tissue engineering and regenerative medicines, toxicity testing, research, drug discovery, bioproduction. The segment is estimated to register the highest CAGR in the market during the forecast period.
Lonza, Thermo Fisher Scientific Inc., Sigma-Aldrich Corporation (MERCK KGaA), Cytiva (Danaher), PAN Biotech, Corning Incorporated, European Collection of Cell Cultures (ECACC), Bovogen Biologicals Pty Ltd., WuXi AppTec, and American Type Culture Collection (ATCC) among others are among the leading companies operating in the cell line development serum market.
The report segments global cell line development serum market as follows:
By Type
- Fetal Bovine Serum
- Adult Bovine Serum
- Porcine Serum
- Horse Serum
- Other Animal Serum
By Application
- Bioproduction
- Drug Discovery
- Tissue Engineering and Regenerative Medicines
- Toxicity Testing
- Academic Research
By Geography
- North America
- Europe
- France
- Germany
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific (APAC)
- China
- India
- Japan
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East & Africa (MEA)
- Saudi Arabia
- UAE
- South Africa
- Rest of Middle East & Africa
- South and Central America (SCAM)
- Brazil
- Argentina
- Rest of South and Central America
